Home >  Medicine >  Medicine News >  Azithromycin if taken...

Azithromycin if taken during pregnancy reduces LBW and premature births: Lancet

Written By :  Hina Zahid
Medically Reviewed By :  Dr. Kamal Kant Kohli
Published On 2021-09-22 05:17 GMT   |   Update On 2021-09-22 09:47 GMT
Advertisement

A common antibiotic azithromycin has been found to reduce low birth weight and premature births, if taken during pregnancy, in countries where malaria is endemic, according to a research review led by the Murdoch Children's Research Institute (MCRI).

The researchers found that azithromycin reduced low birth weight and prematurity in Africa and Asia but didn't lower infant deaths, infections and hospital admissions.

The systematic review has been published in The Lancet EClinicalMedicine.

The researchers reviewed 14 studies undertaken in African and Asian countries, involving 17,594 participants.

Azithromycin is an inexpensive antibiotic widely used to treat chest and ear infections. In pregnancy it has been specifically used in the past to treat STIs and, alongside other antimalarial drugs, to prevent adverse consequences of malaria on maternal and fetal outcomes and caesarean wound infections.
Advertisement
MCRI researcher Dr Maeve Hume-Nixon said it was unclear whether azithromycin would improve perinatal and neonatal outcomes in non-malaria endemic settings, and the potential harm on stillbirth rates needed further investigation.
Dr Hume-Nixon said these findings emphasised the importance of similar MCRI-led research currently being done in Fiji.

"This review found that there was uncertainty about the potential benefits of this intervention on neonatal deaths, admissions and infections, and potential harmful effects on stillbirth despite biological reasons why this intervention may have benefits for these outcomes," she said.
"Therefore, results from studies like ours underway in Fiji will help to better understand the effect of this intervention on these outcomes."
The Bulabula MaPei study is a randomised controlled clinical trial testing if azithromycin given to women in labour, prevents maternal and infant infections.
Globally, infections cause about 21 per cent of 2.4 million neonatal deaths each year and 52 per cent of all under five deaths, with a disproportionate amount occurring in low- and middle-income countries.
Infections are also common in mothers with about five million cases of pregnancy-related infections occurring each year, resulting in 75,000 maternal deaths.
MCRI Professor Fiona Russell said the large clinical trials in Africa and Asia, along with the MCRI-led trial in Fiji, were likely to inform global policy related to maternal child health and hopefully benefit infants and mothers around the world.
"Administration of azithromycin during labour may be a cheap and simple intervention that could be used to improve neonatal death rates in low and-middle-income countries, alongside strengthening of maternal child health services," she said. "This study, together with other large clinical trials, will add to evidence for the consideration of new international maternal and child health guidelines."
Researchers from the University of Melbourne and The Royal Children's Hospital also contributed to the review.
https://www.thelancet.com/journals/eclinm/article/PIIS2589-5370(21)00403-X/fulltext


Tags:    
Article Source : The Lancet EClinicalMedicine

Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.

NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.

Hina Zahid

Hina Zahid Joined Medical Dialogue in 2017 with a passion to work as a Reporter. She coordinates with various national and international journals and association and covers all the stories related to Medical guidelines, Medical Journals, rare medical surgeries as well as all the updates in the medical field. Email: editorial@medicaldialogues.in. Contact no. 011-43720751

Comments Policy
Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Similar News

Sulfonylureas Linked to Higher Cardiovascular Risk in Type 2 Diabetes: Study Shows

New research supports Ivermectin as an effective strategy to control malaria transmission

This Night-Time Snack May Alter Gut Bacteria and Support Metabolic Health: Study Finds

Vitamin D supplementation reduced IBD-related hospitalizations and corticosteroid use: Study

Yoga May Reduce the Risk of Developing Diabetes by 40 Percent: Study Shows

Longer Antibiotic Therapy and Early PCN Drainage Linked to Better Outcomes in Urosepsis with Upper Ureteral Stones: Study

Hydroxychloroquine Use Linked to Slower Kidney Function Decline in Lupus Nephritis Patients: Study Finds

No Major Advantage Seen With mPCR and Procalcitonin Combo in ICU-Treated Pneumonia: MULTI-CAP Trial